Cargando…
The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis
BACKGROUND: Rituximab has been frequently used as a second-line treatment for patients with immune thrombocytopenia (ITP). The optimal dose and course of rituximab are uncertain. METHODS: A comprehensive search for randomized controlled trials reporting the use of low-dose (100 mg) or standard-dose...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514896/ https://www.ncbi.nlm.nih.gov/pubmed/34660807 http://dx.doi.org/10.1155/2021/9992086 |